Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma

Giuseppe Procopio, Elena Verzoni, Arpine Gevorgyan, Maddalena Mancin, Sara Pusceddu, Laura Catena, Marco Platania, Valentina Guadalupi, Antonia Martinetti, Emilio Bajetta

Research output: Contribution to journalArticle


Background: The aim of our study was to evaluate the efficacy and safety in unresectable or advanced renal carcinoma treated with sorafenib, in a situation closely similar to the everyday medical practice. Patients and Methods: One hundred and thirty-six patients have been treated with 400 mg b.i.d. of sorafenib administered orally until disease progression or unacceptable toxicity. They were either previously untreated or relapsed after one or more previous treatments with systemic therapy. Most of them had clear cell renal carcinoma (RCC), but other histological types such as papillary, chromophobe, Bellini ducts, sarcomatoid and mixed forms were also represented. Results: Overall disease control of 70.6% was achieved with 7.9% of partial remissions. Response was observed in the majority of patients with RCC, but also in some patients with non-clear cell RCC. Safety was acceptable, with the most common adverse events consisting of hand-foot skin reaction, cutaneous rash, diarrhoea, fatigue and hypertension. Conclusions: The results confirm previous ones reported in the literature concerning the efficacy and the safety of sorafenib as second-line treatment in patients with RCC. In addition, they disclose the hypothesis that sorafenib could be effective also in patients who underwent multiple previous treatments and in those with histology different from clear cells.

Original languageEnglish
Pages (from-to)204-209
Number of pages6
Issue number3-4
Publication statusPublished - Apr 2008


  • Drug-related toxicity
  • Multikinase inhibitor
  • Renal cell cancer
  • Sorafenib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this